Kezar Life Sciences

Please note: The information displayed on this page might be outdated.
Kezar Life Sciences:
Clinical stage biotechnology company pioneering first-in-class, small molecule therapies designed to inhibit multiple disease-driving cellular pathways by targeting key intracellular proteins. The Company is advancing two differentiated therapeutic approaches: Selective Immunoproteasome Inhibition, for the treatment of autoimmune diseases through immune modulation versus direct immunosuppression; and Protein Secretion Inhibition, halting the secretion of target proteins that contribute to a range of cancers and autoimmune diseases. Lead candidate, zetomipzomib (KZR-616), a selective immunoproteasome inhibitor, is being evaluated in Phase 2 clinical trials for lupus nephritis and autoimmune hepatitis, and KZR-261, a first-in-class inhibitor of the Sec61 translocon developed using the Company’s novel discovery Protein Secretion Inhibition Platform, is undergoing a Phase 1 clinical trial for the treatment of advanced/metastatic solid tumors.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - Pacific
Clinical Stage
Phase l or ll
Disease Space
Autoimmune, Oncology
Industry
Biotechnology
Listing
Public, USA
Market Cap
<100MM
Therapeutic Modalities
Small Molecule
Website:
Profiles:
Address:
4000 Shoreline Court
Suite 300
South San Francisco, CA 94080
United States
Suite 300
South San Francisco, CA 94080
United States
More info:
My account:
Company Participants at Solebury 1x1 Management Access Event 2023
- Christopher Kirk, PRESIDENT & CHIEF SCIENTIFIC OFFICER, CO-FOUNDER
- John Fowler, CEO, Co-Founder
- Marc L. Belsky, Chief Financial Officer
- Nick Mordwinkin , PhD, Chief Business Officer
- Noreen Henig, MD, CMO
Top 10 Holders of Kezar Life Sciences Inc
Institution | OS (%) | Position | Mkt Val ($MM) | Source | Filing Date |
---|---|---|---|---|---|
Suvretta Capital Management LLC | 9.90 | 7,167,591 | 8.53 | 13F | 6/30/23 |
Avidity Partners Management LP | 8.40 | 6,080,000 | 7.24 | 13F | 6/30/23 |
OrbiMed Advisors LLC | 7.54 | 5,463,000 | 6.50 | 13F | 6/30/23 |
Prosight Management LP | 6.42 | 4,651,920 | 5.54 | 13F | 6/30/23 |
Millennium Management LLC | 5.17 | 3,741,109 | 4.45 | 13F | 6/30/23 |
Vanguard Group, Inc. (Subfiler) | 4.12 | 2,982,519 | 3.55 | 13F | 6/30/23 |
BlackRock Fund Advisors | 4.07 | 2,949,364 | 3.51 | 13F | 6/30/23 |
Sphera Funds Management Ltd. | 2.75 | 1,988,228 | 2.37 | 13F | 6/30/23 |
OrbiMed Advisors Private Equity | 2.65 | 1,927,000 | 2.29 | Funds | 8/31/23 |
Granahan Investment Management, LLC | 2.62 | 1,899,019 | 2.26 | 13F | 6/30/23 |
Ownership data is sourced through FactSet.
Stock Market Data
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2023 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by
QuoteMedia.
Terms of Use.